Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results for the fourth period* and eleven months ended...
Author: @admin
Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
SAN DIEGO – April 29, 2020 – Amplyx Pharmaceuticals, a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy, Ph.D., President and Chief Executive Officer, will participate in a panel discussing fungal pathogens and the emerging antifungal therapeutic landscape at the...
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector
SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that...
Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference
SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two panels discussing antifungal and COVID-19 therapies at the upcoming Infectious Disease Virtual Conference...
Entasis Therapeutics Completes Initial Closing of $35M Private Placement with Innoviva
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) (“Entasis”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that it has completed the initial $3.3 million closing of a $35 million common stock and warrant securities investment with Innoviva Inc. (NASDAQ: INVA)...
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints Ibrexafungerp was generally safe and well-tolerated Positive results...
Melinta Therapeutics Successfully Completes Financial Restructuring
Company is Well-Positioned for Success as it Emerges from Chapter 11 In Partnership with Deerfield, Plans for Growth are Announced NEW YORK, NY, April 20, 2020—Commercial-stage antibiotics company Melinta Therapeutics (“Melinta”) and healthcare investment firm Deerfield Management Company, L.P. (“Deerfield”), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter...
Melinta Therapeutics Successfully Completes Financial Restructuring
Company is Well-Positioned for Success as it Emerges from Chapter 11 In Partnership with Deerfield, Plans for Growth are Announced NEW YORK, NY, April 20, 2020—Commercial-stage antibiotics company Melinta Therapeutics (“Melinta”) and healthcare investment firm Deerfield Management Company, L.P. (“Deerfield”), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter...
Summit Appoints Robert W. Duggan as Chief Executive Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) Duggan has been appointed Chief Executive Officer (‘CEO’) of Summit Therapeutics, effective immediately. Mr Duggan will retain his...
Summit Appoints Robert W. Duggan as Chief Executive Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Chief Executive Officer Oxford, UK, and Cambridge, MA, US, 14 April 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr Robert (Bob) Duggan has been appointed Chief Executive Officer (‘CEO’) of Summit Therapeutics, effective immediately. Mr Duggan will retain his...